NLRC5 Might Promote Endometrial Cancer Progression by Inducing PD-L1 Expression

Su-Ding Zhu1, Jing Zhang1, Xiao-Jing Liu1

  • 1533251The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, People's Republic of China.

Insights

NOD-like receptor (NLR) family, caspase recruitment (CARD) domain containing 5 (NLRC5) inhibits programmed cell death protein ligand 1 (PD-L1) in endometrial cancer (EC). Mutations in specific genes may cause NLRC5 downregulation, impacting PD-L1 levels in EC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Endometrial cancer (EC) is associated with dysregulation of the NOD-like receptor (NLR) family, caspase recruitment (CARD) domain containing 5 (NLRC5).
  • The precise role of NLRC5 and its regulatory mechanisms in EC, particularly concerning programmed cell death protein ligand 1 (PD-L1), remain largely unexplored.

Purpose of the Study:

  • To investigate the regulatory relationship between NLRC5 and PD-L1 in endometrial cancer.
  • To identify molecular factors contributing to NLRC5 inactivation in EC.

Main Methods:

  • Immunohistochemistry to assess NLRC5 and PD-L1 expression in endometrial tissues.
  • Pearson's correlation analysis to determine expression correlations.
  • Immunofluorescence, western blotting, and qRT-PCR to evaluate NLRC5's role in PD-L1 expression in EC cell lines.
  • Whole-exome sequencing (WGS) for somatic mutation analysis in EC patients.

Main Results:

  • NLRC5 expression was significantly downregulated in EC tissues compared to normal endometrium.
  • PD-L1 expression was elevated in EC tissues, showing a negative correlation with NLRC5 levels.
  • NLRC5 was found to inhibit PD-L1 expression in EC cell lines.
  • Mutations in ANKRD20A2, C2orf42, ADGRB3, AVPR2, GOLGA6C, and IPPK were identified as potential causes for NLRC5 downregulation in EC.

Conclusions:

  • NLRC5 acts as an inhibitor of PD-L1 activation in endometrial cancer.
  • Genetic mutations in ANKRD20A2, C2orf42, ADGRB3, AVPR2, GOLGA6C, and IPPK may contribute to NLRC5 downregulation in EC.
  • Further research is warranted to elucidate the detailed mechanisms of NLRC5 in PD-L1 regulation and the role of these identified genes in NLRC5 inactivation.